Idexx Laboratories Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Idexx Laboratories Inc's ROA in the second quarter of 2026?
Idexx Laboratories Inc achieved a return on average assets (ROA) of 33.61 % in its second quarter of 2026 a new company high.

ROA has improved compared to 32.56% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 29 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 117, from total ROA ranking in the first quarter of 2026 at 148.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	3.35 %	5.35 %	5.41 %	4.8 %	1.04 %
Y / Y Net Income Change	15.11 %	14.74 %	14.82 %	17.94 %	44.61 %
Net Income (TTM) in million	1,140	1,095	1,059	1,027	986
Return On Assets (TTM)	33.61 %	32.56 %	31.91 %	31.35 %	30.43 %
IDXX's Total Ranking	# 117	# 148	# 144	# 138	# 155
Total Assets (TTM) in million	3,442	3,385	3,351	3,387	3,331
Seq. Total Assets Change	1.68 %	1.04 %	-1.06 %	1.68 %	3.64 %
Seq. Net Income Change	21.54 %	12.19 %	-9.62 %	-6.59 %	21.14 %

IDXX's 5 Years Annual ROA >> Back to IDXX Management Effectiveness >> Compare IDXX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 0
Sector	# 30
Overall	# 111

Return On Assets Statistics
High	Average	Low
33.61 %	22.37 %	12.04 %
(Jun 30 2026)		(Sep 30 2015)

Financial Statements
Idexx Laboratories Inc's Assets	$ 3,442 million	IDXX's Balance sheet
Idexx Laboratories Inc's Income	$ 338 million	Quarterly IDXX's Income Statement
IDXX's Income by Division		See IDXX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	5.41 %	1.05 %	19.6 %	7.93 %	6.22 %
Total Assets in million	3,351	3,179	3,146	2,630	2,437
Y / Y Net Income Change	19.33 %	5.07 %	24.44 %	-8.83 %	27.95 %
Net Income in million	1,059	888	845	679	745
Annual Return On Assets	31.62 %	27.93 %	26.86 %	25.82 %	30.56 %

IDXX's 5 Years Annual ROA >> Back to IDXX Management Effectiveness >> Compare IDXX ROA to its Competitors

Comment on IDXX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 31.62 % compared to prior year, due to annual net income growth of 19.33 % to $1,059.46 million, while value of Idexx Laboratories Inc's overall assets grew just by 5.41 % to $3,350.76 million, compared to $3,350.76 a year before.

More Return On Assets Ratios
IDXX's' Return on Assets at Yahoo Finance
In Vitro & In Vivo Diagnostic Substances Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IDXX's Roa Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IDXX's Competitors
Subscribers only: Roa for Idexx Laboratories Inc's Suppliers
Subscribers only: Return On Assets for IDXX's Customers

You may also want to know
IDXX's Roi	IDXX's Inventory Turnover Ratio	IDXX's Growth Rates	IDXX's Dividend Comparisons
	IDXX's Profitability Ratios	IDXX's Asset Turnover Ratio	IDXX's Dividend Growth
IDXX's Roe	IDXX's Valuation Ratios	IDXX's Financial Strength Ratios	IDXX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Arbutus Biopharma Corp	82.34 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %

Date modified: 2026-09-12T06:10:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.